Answers are grounded in this paper and cite their sources.
Atrial high-rate episodes (AHREs), detected by endovascularly-placed cardiac implanted electronic devices, have been linked to atrial fibrillation (AF), stroke, and mortality with the role of anticoagulation (AC) unclear. We conducted a meta-analysis to assess outcomes among individuals with no prior history of AF who experienced AHREs. Multiple databases were searched for studies assessing outcomes in individuals with no prior history of AF who experienced AHREs. A fixed-effects model was used to calculate risk ratios (RRs) with 95% confidence intervals. Outcomes assessed were clinical AF, stroke, mortality, major bleeding on anticoagulation, and thromboembolism on anticoagulation. A total of 10 studies with a combined enrollment of 9576 patients were identified. 5 were unmatched retrospective case-control studies, 2 were prospective cohort studies, 1 was a matched retrospective case-control study, 1 was a single-blinded randomized trial, and 1 was a double-blinded randomized trial. There was a significantly increased risk of clinical AF (RR 4.06; 95% CI 2.83 - 5.83; P <.00001) and major bleeding on anticoagulation (RR 1.65; 95% CI 1.06 - 2.56; P =.03).Risks of stroke (RR 1.66; 95% CI .91 - 3.03; P =.1), mortality (RR 1.3; 95% CI .82 - 2.05; P =.26), and thromboembolism on anticoagulation (RR .68; 95% CI .41-1.14; P =.14) were insignificant. While there is an increased risk of clinical AF in those with AHREs, the decision to initiate anticoagulation may be futile given the increased risk of major bleeding and the lack of benefit in mitigating thromboembolism. Further studies are needed to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: